MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Home・Aktien・Vivani Medical

Vivani Medical

Geschlossen

1.19 -1.65

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.17

Max

1.23

Schlüsselkennzahlen
By Trading Economics
Angestellte	37

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+225.2% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. März 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-22M 82M
Vorheriger Eröffnungskurs	2.84
Vorheriger Schlusskurs	1.19

Vivani Medical Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Dez. 2025, 22:20 UTC

Wichtige Markttreiber

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31. Dez. 2025, 17:31 UTC

Wichtige Markttreiber

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31. Dez. 2025, 16:30 UTC

Wichtige Markttreiber

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31. Dez. 2025, 15:19 UTC

Wichtige Markttreiber

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31. Dez. 2025, 15:17 UTC

Wichtige Markttreiber

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31. Dez. 2025, 14:37 UTC

Wichtige Markttreiber

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. Dez. 2025, 21:13 UTC

Akquisitionen, Fusionen, Übernahmen

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31. Dez. 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31. Dez. 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31. Dez. 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31. Dez. 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31. Dez. 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31. Dez. 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31. Dez. 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31. Dez. 2025, 17:16 UTC

Wichtige Markttreiber

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31. Dez. 2025, 17:00 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31. Dez. 2025, 15:57 UTC

Akquisitionen, Fusionen, Übernahmen

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31. Dez. 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31. Dez. 2025, 15:02 UTC

Wichtige Markttreiber

Nike Shares Rise After CEO Hill Buys $1M of Shares

31. Dez. 2025, 14:40 UTC

Akquisitionen, Fusionen, Übernahmen

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31. Dez. 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31. Dez. 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31. Dez. 2025, 13:01 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31. Dez. 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

31. Dez. 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

31. Dez. 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31. Dez. 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31. Dez. 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Peer-Vergleich

Kursveränderung

Vivani Medical Prognose

Kursziel

By TipRanks

225.2% Vorteil

12-Monats-Prognose

Durchschnitt 4 USD 225.2%

Hoch 4 USD

Tief 4 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vivani Medical – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vivani Medical – Dist abgegeben haben.

Finanzen

Über Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.